CA2357986C - Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques - Google Patents

Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques Download PDF

Info

Publication number
CA2357986C
CA2357986C CA2357986A CA2357986A CA2357986C CA 2357986 C CA2357986 C CA 2357986C CA 2357986 A CA2357986 A CA 2357986A CA 2357986 A CA2357986 A CA 2357986A CA 2357986 C CA2357986 C CA 2357986C
Authority
CA
Canada
Prior art keywords
alkyl
nucleic acids
group
nucleic acid
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2357986A
Other languages
English (en)
Other versions
CA2357986A1 (fr
Inventor
Roderic M. K. Dale
Steven L. Gatton
Amy Arrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oligos Etc Inc
Original Assignee
Oligos Etc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oligos Etc Inc filed Critical Oligos Etc Inc
Publication of CA2357986A1 publication Critical patent/CA2357986A1/fr
Application granted granted Critical
Publication of CA2357986C publication Critical patent/CA2357986C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des acides nucléiques à extrémités bloquées tels que, par exemple, des oligonucléotides 2'-O-R, 2'-O-R-O-R, 3'-O-R et 3'-O-R-O-R, possédant une stabilité de pH faible, une résistance aux nucléases et éventuellement des propriétés antibactériennes. Ces acides nucléiques à extrémités bloquées, à faible toxicité, à haute spécificité et à stabilité acide représentent une nouvelle structure d'oligonucléotides améliorée destinée au traitement par voie thérapeutique d'affections. Les polymères résistants aux exonucléases à stabilité acide 3' et 5' de la présente invention possèdent des effets antibactériens lors de leur application in vivo, c.-à-d. lors de leur application topique sur une peau présentant des sites effectifs d'infection chez les chiens et les humains.
CA2357986A 1998-12-30 1999-12-16 Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques Expired - Lifetime CA2357986C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22349898A 1998-12-30 1998-12-30
US09/223,498 1998-12-30
US35606999A 1999-07-19 1999-07-19
US09/356,069 1999-07-19
PCT/US1999/030266 WO2000040592A1 (fr) 1998-12-30 1999-12-16 Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques

Publications (2)

Publication Number Publication Date
CA2357986A1 CA2357986A1 (fr) 2000-07-13
CA2357986C true CA2357986C (fr) 2014-02-11

Family

ID=26917847

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2357986A Expired - Lifetime CA2357986C (fr) 1998-12-30 1999-12-16 Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques

Country Status (5)

Country Link
EP (1) EP1140966A1 (fr)
JP (1) JP4688294B2 (fr)
AU (1) AU2197600A (fr)
CA (1) CA2357986C (fr)
WO (1) WO2000040592A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781577B2 (en) * 1998-12-30 2005-06-02 Lakewood-Amedex, Inc. Therapeutic phosphodiesterase inhibitors
CA2453362A1 (fr) 2001-07-10 2003-01-23 Oligos Etc. Inc. Compositions pharmacologiques contenant des oligonucleotides et leur utilisation
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen
JPWO2012070618A1 (ja) 2010-11-24 2014-05-19 株式会社カネカ 増幅核酸検出方法及び検出デバイス
CN104254620B (zh) * 2012-04-27 2022-11-08 株式会社钟化 核酸的扩增方法及扩增核酸的检测方法
US20160068901A1 (en) * 2013-05-01 2016-03-10 Advanced Liquid Logic, Inc. Analysis of DNA
US10392652B2 (en) 2013-11-22 2019-08-27 Kaneka Corporation Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end
US20170016894A1 (en) * 2015-07-15 2017-01-19 Orizhan Bioscience Limited Detection Comprising Signal Amplifier
JP7132911B2 (ja) 2016-09-16 2022-09-07 バイオ－パス ホールディングス， インコーポレイテッド リポソームアンチセンスオリゴヌクレオチドとの併用療法
JP7284709B2 (ja) * 2017-04-19 2023-05-31 バイオ－パス ホールディングス， インコーポレイテッド Ｂｃｌ２阻害のためのｐ－エトキシ核酸
US11104941B2 (en) 2018-09-28 2021-08-31 Bioo Scientific Corporation 5′ adapter comprising an internal 5′-5′ linkage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4037363A1 (de) * 1990-04-09 1991-10-10 Europ Lab Molekularbiolog 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
US5658731A (en) * 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
JPH07501314A (ja) * 1991-05-10 1995-02-09 ハイブライドン　インコーポレイテッド ３′−末端封鎖されたオリゴヌクレオチド
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
IT1271684B (it) * 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
WO1996039414A1 (fr) * 1995-06-01 1996-12-12 Hybridon, Inc. Groupes nouveaux de protection des bases pendant la synthese d'oligonucleotides
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides

Also Published As

Publication number Publication date
JP4688294B2 (ja) 2011-05-25
CA2357986A1 (fr) 2000-07-13
EP1140966A1 (fr) 2001-10-10
WO2000040592A8 (fr) 2000-11-09
JP2002534434A (ja) 2002-10-15
WO2000040592A1 (fr) 2000-07-13
AU2197600A (en) 2000-07-24

Similar Documents

Publication Publication Date Title
EP1140965B1 (fr) Oligonucleotides protonés antibacteriens
DE69008521T2 (de) Kovalente konjugate von lipiden und oligonukleotiden.
DE69513998T2 (de) Verwendung von 2'-substituierten oligonukleotiden zur reduzierung der genexpression
EP1313768B1 (fr) Oligonucleotides antisens contre vr1
DE69931029T2 (de) Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen
DE69629702T2 (de) Liposomale oligonukleotidzusammensetzungen
DE69233117T2 (de) In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen
US6001989A (en) Nucleotide based endonucleases
CA2357986C (fr) Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques
EP2079313A2 (fr) Composés antimicrobiens et antiviraux et leurs procédés d'utilisation
JP4787409B2 (ja) 治療用ホスホジエステラーゼ阻害剤
EP1204430B1 (fr) Conjugats et procedes permettant de les preparer, et leur utilisation pour transporter des molecules par l'intermediaire de membranes biologiques
DE69613984T2 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
DE19750702A1 (de) Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo
DE69302369T2 (de) Erhöhung der katalytischen Aktivität von Ribozymen mit einem benachbartem Oligonukleotid als Heffer
AU2004226974B2 (en) Protonated/acidified nucleic acids and methods of use
DE60208400T2 (de) Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide
DE10006572A1 (de) Oligonucleotid-Konjugate
US6008343A (en) Nucleotide based endonucleases
DE69835525T2 (de) Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden
AU650032B2 (en) Endonucleases

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20191216